| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | RAI; NSHC; SHCC; N-Shc |
| WB Predicted band size | 64 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human SHC3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SHC3抗体的3篇示例参考文献(部分信息为假设性示例，供参考)：
---
1. **文献名称**：*"SHC3 expression correlates with neuroblastoma prognosis and regulates tumor cell migration"*
**作者**：Saito Y, et al.
**摘要**：本研究利用SHC3特异性抗体进行免疫印迹和免疫组化分析，发现SHC3在侵袭性神经母细胞瘤中高表达，且与患者预后不良相关。实验表明SHC3通过激活ERK信号通路促进肿瘤细胞迁移。
2. **文献名称**：*"Differential roles of SHC isoforms in neuronal development revealed by antibody-specific knockdown"*
**作者**：Pelicci G, et al.
**摘要**：通过SHC3抗体介导的功能阻断实验，研究者发现SHC3在中枢神经系统发育中调控轴突导向，且其表达模式与SHC1/SHC2存在显著差异，提示亚型特异性功能。
3. **文献名称**：*"SHC3 as a biomarker for trastuzumab resistance in HER2-positive breast cancer"*
**作者**：Smith LM, et al.
**摘要**：研究利用SHC3抗体检测乳腺癌组织样本，发现SHC3过表达与HER2靶向治疗耐药性相关。机制研究表明SHC3通过增强PI3K/AKT通路活性削弱药物敏感性。
---
**注**：以上文献为模拟示例，实际引用需查询PubMed或专业数据库(如PMID编号)。若需真实文献，建议以关键词“SHC3 antibody”或“SHC3 (SHC-transforming protein 3)”检索最新研究。
The SHC3 antibody targets the SHC (Src homology 2 domain-containing transforming protein C3), a member of the SHC family of adaptor proteins involved in intracellular signaling. SHC proteins, including SHC1. SHC2. SHC3. and SHC4. regulate signal transduction pathways by linking activated receptor tyrosine kinases (RTKs) to downstream effectors like the Ras/MAPK cascade. SHC3. encoded by the *SHC3* gene (also called *NSHC*), is primarily expressed in the nervous system and plays a critical role in neurotrophin signaling, neuronal differentiation, and synaptic plasticity. Structurally, SHC3 contains a phosphotyrosine-binding (PTB) domain, a CH1 region with tyrosine phosphorylation sites, and a CH2 domain, enabling interactions with signaling molecules such as Trk receptors.
SHC3 is implicated in neurological disorders and cancer. In neuroblastoma and other cancers, SHC3 overexpression correlates with tumor progression, metastasis, and drug resistance, likely by enhancing RTK-mediated survival pathways. SHC3 antibodies are essential tools for studying its expression, localization, and function in both physiological and pathological contexts. They are widely used in techniques like Western blotting, immunohistochemistry, and co-immunoprecipitation to investigate SHC3's role in signaling networks and its potential as a therapeutic target. Research on SHC3 antibodies also aids in understanding its tissue-specific signaling dynamics and crosstalk with other pathways, such as PI3K/AKT, in disease mechanisms.
×
